Streptococcus pneumoniae serotype 9V capsular polysaccharide-specific B-cell receptor

The Streptococcus pneumoniae serotype 9V capsular polysaccharide-specific B-cell receptor is a specialized membrane-bound immunoglobulin expressed on the surface of specific B-lymphocytes. Its primary role is the recognition of the capsular polysaccharide of S. pneumoniae serotype 9V, a major pathogen responsible for invasive diseases such as pneumonia, meningitis, and bacteremia (Source: CDC, 2023). Upon binding the 9V antigen, the receptor initiates a cascade of intracellular signals that drive B-cell activation, clonal expansion, and the production of high-affinity antibodies (Source: Janeway's Immunobiology, 2017). This receptor is the fundamental target of various pneumococcal vaccines, including conjugate (PCV13, PCV15, PCV20) and polysaccharide (PPSV23) formulations, which aim to induce protective immunity (Source: WHO, 2019). Serotype 9V is particularly noteworthy for its inclusion in these vaccines due to its historical association with multi-drug resistance and its impact on global health (Source: Clinical Infectious Diseases, 2015). The successful engagement of these receptors is essential for generating the opsonophagocytic antibodies required to neutralize the bacteria and prevent infection (Source: Nature Reviews Immunology, 2018).

Other names

Anti-pneumococcal serotype 9V B-cell receptorSerotype 9V-specific BCRStreptococcus pneumoniae type 9V capsular polysaccharide receptorBCR-Sp9V

Vaccine-mediated stimulation of these B-cell receptors occurs through the binding of serotype 9V capsular polysaccharides, which triggers receptor-mediated signaling and B-cell activation. In conjugate vaccines, this process is enhanced by T-cell help, leading to the generation of high-affinity memory B-cells and long-lived plasma cells that secrete opsonizing antibodies.